Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ME Stock Forecast 2025-2026
$4.00
Current Price
$109.76M
Market Cap
Buy 0
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to ME Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
ME Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-1.2%
1 Year Change
+23.1%
Year-to-Date Change
-49.2%
From 52W High of $7.88
+750.9%
From 52W Low of $0.47
📊 TOP ANALYST CALLS
Did ME Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if 23andMe is one of their latest high-conviction picks.
Latest ME Stock Price Targets & Analyst Predictions
ME has shown a year-to-date change of 23.1% and a 1-year change of -1.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ME. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ME Analyst Ratings
0
Buy
0
Hold
1
Sell
ME Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $4.00
Latest ME Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ME.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2024 | Citigroup | Daniel Grosslight | Neutral | Maintains | $0.47 |
| Aug 10, 2023 | Citigroup | Buy | Maintains | $N/A | |
| May 26, 2023 | Credit Suisse | Outperform | Reiterates | $N/A | |
| May 26, 2023 | Citigroup | Neutral | Maintains | $N/A | |
| Nov 29, 2022 | Berenberg | Buy | Initiates | $N/A | |
| Nov 8, 2022 | Credit Suisse | Outperform | Maintains | $N/A | |
| Sep 22, 2022 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Aug 10, 2022 | Citigroup | Neutral | Maintains | $N/A | |
| May 27, 2022 | Credit Suisse | Outperform | Maintains | $N/A | |
| May 27, 2022 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 11, 2022 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 11, 2022 | Credit Suisse | Outperform | Maintains | $N/A | |
| Dec 20, 2021 | Citigroup | Neutral | Maintains | $N/A | |
| Nov 15, 2021 | Citigroup | Neutral | Downgrade | $N/A | |
| Nov 11, 2021 | Credit Suisse | Outperform | Maintains | $N/A | |
| Aug 17, 2021 | Credit Suisse | Outperform | Initiates | $N/A | |
| Aug 16, 2021 | Citigroup | Buy | Maintains | $N/A | |
| Jul 12, 2021 | Citigroup | Buy | Initiates | $N/A |
23andMe Holding Co. (ME) Competitors
The following stocks are similar to 23andMe based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
23andMe Holding Co. (ME) Financial Data
23andMe Holding Co. has a market capitalization of $109.76M with a P/E ratio of -0.4x. The company generates $189.90M in trailing twelve-month revenue with a 52.7% profit margin.
Revenue growth is -43.7% quarter-over-quarter, while maintaining an operating margin of -94.4% and return on equity of +1,050.4%.
Valuation Metrics
Market Cap
$109.76M
Enterprise Value
$139.94M
P/E Ratio
-0.4x
PEG Ratio
0.0x
Price/Sales
0.6x
Growth & Margins
Revenue Growth (YoY)
-43.7%
Gross Margin
+53.2%
Operating Margin
-94.4%
Net Margin
+52.7%
EPS Growth
-37.1%
Financial Health
Cash/Price Ratio
N/A
Current Ratio
0.5x
Debt/Equity
-1.0x
ROE
+1,050.4%
ROA
-175.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
23andMe Holding Co. (ME) Business Model
About 23andMe Holding Co.
What They Do
Consumer genetics testing and therapeutics development.
Business Model
The company generates revenue through its two main segments: Consumer and Research Services, which offers genetic testing and telehealth consultations, and Therapeutics, which focuses on developing and commercializing novel therapies. The Consumer segment provides genetic reports and health insights, while the Therapeutics segment engages in R&D and out-licensing of drug candidates.
Additional Information
Founded in 2006 and headquartered in South San Francisco, California, the company has faced financial challenges, filing for Chapter 11 reorganization in March 2025. Collaborations with other firms, such as Mirador Therapeutics, highlight its strategic partnerships in advancing therapeutic innovations.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
560
CEO
Mr. Joseph Selsavage
Country
United States
IPO Year
2021
Website
www.23andme.com23andMe Holding Co. (ME) Latest News & Analysis
Latest News
Quick Summary
The House Energy and Commerce Committee expressed concerns about 23andMe's genetic data security amid the company's Chapter 11 bankruptcy filing and asset sale.
Why It Matters
Concerns over data security and bankruptcy raise red flags about 23andMe's viability and potential asset value, impacting investor confidence and future market performance.
Source: CNBC
Market Sentiment:
Negative
Quick Summary
A U.S. House committee is investigating 23andMe's potential sale of genetic data amid its bankruptcy, asking the co-founder to testify next month.
Why It Matters
The investigation into 23andMe highlights potential risks in genetic data privacy, impacting investor confidence and the company's valuation amid bankruptcy proceedings.
Source: Reuters
Market Sentiment:
Negative
23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors
7 months ago
Quick Summary
Sen. Bill Cassidy is investigating 23andMe's bankruptcy filing to ensure the company does not sell customer data to China or other foreign adversaries.
Why It Matters
Concerns over potential data sales to foreign adversaries could impact 23andMe's reputation and regulatory scrutiny, affecting investor confidence and stock performance.
Source: Fox Business
Market Sentiment:
Negative
What's next for 23andMe and all that DNA data?
8 months ago
Quick Summary
23AndMe has filed for bankruptcy, raising concerns among customers about the future of their DNA data and its implications for the genetic testing industry.
Why It Matters
23AndMe's bankruptcy raises concerns over the security and ownership of genetic data, potentially impacting consumer trust and the broader genetic testing market's viability.
Source: Bloomberg Markets and Finance
Market Sentiment:
Negative
Gulp Data Estimates 23andMe's Data Assets to Be Worth $289 Million Amid Bankruptcy Concerns
7 months ago
Quick Summary
Gulp Data values 23andMe's data assets at $289 million amid concerns over the company's financial struggles and the future of its genetic database.
Why It Matters
The valuation of 23andMe's data assets at $289 million highlights potential investment risks and opportunities, particularly amid financial struggles affecting its future and data value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
FTC Chairman Andrew Ferguson stated that any buyer of 23andMe assets must adhere to the company's current privacy policy.
Why It Matters
The FTC's stance on 23andMe's privacy policy may impact the company's valuation and attractiveness to potential buyers, influencing investment decisions in the biotech sector.
Source: New York Post
Market Sentiment:
Negative
Frequently Asked Questions About ME Stock
What is 23andMe Holding Co.'s (ME) stock forecast for 2026?
Analyst forecasts for 23andMe Holding Co. (ME) are not currently available. The stock is trading at $4.00.
Is ME stock a good investment in 2026?
According to current analyst ratings, ME has 0 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $4.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ME stock?
Price predictions from Wall Street analysts for ME are not currently available. The stock is trading at $4.00.
What is 23andMe Holding Co.'s business model?
The company generates revenue through its two main segments: Consumer and Research Services, which offers genetic testing and telehealth consultations, and Therapeutics, which focuses on developing and commercializing novel therapies. The Consumer segment provides genetic reports and health insights, while the Therapeutics segment engages in R&D and out-licensing of drug candidates.
What is the highest forecasted price for ME 23andMe Holding Co.?
Price targets from Wall Street analysts for ME are not currently available. The stock is trading at $4.00.
What is the lowest forecasted price for ME 23andMe Holding Co.?
Price targets from Wall Street analysts for ME are not currently available. The stock is trading at $4.00.
What is the overall ME consensus from analysts for 23andMe Holding Co.?
The overall analyst consensus for ME is bearish. Out of 2 Wall Street analysts, 0 rate it as Buy, 0 as Hold, and 1 as Sell.
How accurate are ME stock price projections?
Stock price projections, including those for 23andMe Holding Co., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 1:31 AM UTC